Published transfer-BO comparisons often estimate an average treatment effect of acquisition choice over hidden regime variables, while practitioners need the conditional effect for their specific prior quality, budget ratio, and metric. An audit of 40 transfer-BO papers from NeurIPS, ICML, ICLR, AISTATS, UAI, TMLR, JMLR, and AutoML-Conf (2022-2025) finds that 98% never vary B/|A| as a controlled axis. On the same GDSC2 benchmark, changing only the budget reverses the ranking: at B=50, Greedy outperforms UCB by 0.050 Hit@1, while at B=100, UCB outperforms Greedy by 0.035. We capture this transition with the Portable Regime Score PRS=(B/|A|)(1-rho), where rho is the prior rank correlation and can be estimated from pilot contexts before the main comparison. Across 79 conditions spanning chemistry, drug-response biology, and HPO, a hierarchical model gives beta=0.50 (p=1.1e-9), and 19% of conditions fall in an equivalence zone where |advantage|<0.01 Hit@1. In five published reversal cases, PRS predicts the winner from pre-comparison observables. A No-Free-Leaderboard proposition explains why unconditional rankings are unstable: when CATE changes sign across regimes, the reported ATE becomes a function of benchmark mixture. RegimePlanner, which estimates rho online and switches acquisition accordingly, wins all 16 HPO-B search spaces at B=100 and exceeds the matched {Greedy,UCB} per-context oracle on GDSC2 by 18%. Pre-registered predictions achieve 27/40=67.5% overall accuracy and above 90% within EMA prior families. The practical protocol is simple: report B/|A|, rho, K, and metric alongside any claimed acquisition advantage.

翻译：暂无翻译